It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
Academic rigour, journalistic flair
Articles on Vaccines
Displaying 281 - 300 of 785 articles
It’s not clear whether the TRIPS agreement is what’s getting in the way of vaccine supply, and waiving intellectual property rights may stifle future innovation.
Plus, a psychologist on how we look back at our big decisions in life. Listen to episode 14 of The Conversation Weekly podcast.
We surveyed social media users from vulnerable groups and found 73% got their vital news from social platforms. How can we protect these people from vaccine misinformation?
It’s quite likely this virus will never be eliminated from the world. But even so, getting vaccinated enormously reduces your risk of severe outcomes like hospitalisation and death.
The CDC first paused, then unpaused, the administration of the Johnson & Johnson COVID-19 vaccine due to concerns about blood clots. But what are those clots, and how do they form?
Reports have suggested some women are experiencing changes to their menstrual cycles after having a COVID vaccine.
COVID has now claimed over 200,000 lives on the subcontinent, and the knock-on effects are likely to be substantial.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
Older adults are assets, but they shouldn’t be commodities.
The COVID-19 vaccination programme requires stringent data collection and transparency.
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
COVID-19 has shown us that we are not “all in this together” despite what politicians may want us to think.
It’s normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won’t tell you which you are.
As more people get vaccinated and different facets of society slowly reopen, challenges remain in the nation’s quest to get back to normal. Here are five articles that help illuminate the path.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
India and South Africa are pressing the World Trade Organization to waive patent rights to help ramp up vaccine production. There’s a better solution.
Generally speaking, fault can only be proven when the doctor has acted outside of the professional standard of care.
COVAX, the global vaccine distribution initiative, is well behind its goal of delivering 2 billion doses this year due to under-investment, vaccine nationalism and export restrictions.
This year is a whole new ball game for pandemic politics. For a prime minister not accustomed to pressure, Scott Morrison is proving far less equipped.
Top contributors
-
Professorial Fellow, University of Canberra
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor of Biology, Rochester Institute of Technology
-
Lecturer in Virology, Queen's University Belfast
-
Professor of Immunology, RMIT University
-
Senior Lecturer; MD, Victoria University
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Professor, Discipline of Paediatrics and Child Health, University of Sydney
-
Assistant Professor of Political Science, Oklahoma State University
